Biosimilars
- Korean Biotech at BIO USA 2026: Licensing Deals Over Product Launches
Korean drugmakers used BIO USA 2026 to court partners rather than launch products, with Curacle's 1.6 trillion won deal setting the benchmark.
Korean drugmakers used BIO USA 2026 to court partners rather than launch products, with Curacle's 1.6 trillion won deal setting the benchmark.